A Phase 1/2 Study to define the objective response rate of Paediatric Patients with Relapsed, Recurrent or Progressive Neuroblastoma to Valproate in Combination with Interferon alpha

Australian and New Zealand Children's Haematology and Oncology Group0 个研究点目标入组 9 人开始时间: 2010年10月6日最近更新: 2021年6月14日

适应症

试验速览

暂无简介。

•Target tumour is neuroblastoma.
•Patient must have one of the following:
•- recurrent disease following aggressive multidrug frontline chemotherapy and autologous transplantation
•- resistent/refractory disease during aggressive multidrug frontline chemotherapy
•Patients must have measurable disease
•Patients must have a performance level of 0, 1, or 2 using Karnofsky scale or Lansky scale
•Patients must have a life expectancy of greater than or equatl to 8 weeks
•Patients must have fully recovered from the actue toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering the study
•Patients must have adequate organ function

•Patients with recurrent or progressive benign lesions without viable malignant neuroblastoma
•Patients do not meet concomitant medication restrictions
•For female patients, pregnancy and breast feeding
•Myeloplastic syndrome
•Uncontrolled infection

发起方

Australian and New Zealand Children's Haematology and Oncology Group